PharmaCyte Biotech, Inc.
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- $30.7M
- Total assets
- $55.2M
- Market cap
- $7.5M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $7.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 11, 2003
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review PharmaCyte Biotech, Inc..